Viatris Inc. (VTRS) said that the United States Court of Appeals for the Federal Circuit denied Biogen's request that the Court reconsider its prior decision affirming the invalidity of Biogen's U.S. Patent No. 8,399,514, covering Tecfidera.
Following the Court's denial of Biogen's rehearing petition, the '514 patent remains invalid.
Viatris' subsidiary Mylan Pharmaceuticals Inc. launched the first therapeutically equivalent substitutable generic to Tecfidera in August 2020.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.